Partly paraphrased from www.functionalmedicineuniversity.com/public/883print.cfm
by Ronald Grisanti D.C., D.A.B.C.O., D.A.C.B.N., M.S.
Medical literature clearly shows that Statin medications impair or shut down the production of one of the most important nutrients in the body- Co-Enzyme Q10 (CoQ10). Prescribing Statin medications without CoQ10 shows lack of scientific knowledge, based upon the wealth of research references listed below. In the 1990s, Merck pharmaceuticals did in fact add CoQ10 to a Statin medication and obtained U.S. patent number 4,933,165. But for unknown reasons this patent never came to the marketplace. See Patent at:
Why would anyone take a Statin without CoQ10… the following should be a wake up call! When CoQ10 is depleted it causes oxidizing of LDL cholesterol -> major inflammation. This inflammation is a set up for myopathy (muscle inflammation, swelling, pain & weakness (which I too frequently see in my clinic). Then increases the risk for a serious syndrome called Rhabdomyolysis due to the muscle injury (rare).
Plus exhaustion, depression resistant to anti-depressants, gum disease & tooth loss, hair loss, liver disease, sudden complete memory loss or amnesia & dementia, cataracts, folic acid deficiency, cell membrane damage. CoQ10 deficiency also increases the risk for high blood pressure, congestive heart failure, angina, cardiomyopathy, such that there is not necessarily a decreased risk of heart attack or stroke.
The reason why Statins are so ubiquitously prescribed is that no other class of cholesterol-lowering drugs is as effective as HMG-CoA Reductase Inhibitors (statins) in lowering LDL (and incidentally C-reactive protein too, which is an inflammatory marker). The LDL goal is 70 to 100 mg/dl. Statins lower LDL levels anywhere from 10 to 60%- GREAT! They also modestly increase HDL level by 5 - 23%, and modestly decrease TG by 10 - 30% (Edmunds & Mayhew, 2013). An all-in-one shot! For best efficacy, Statin drugs are taken once a day at mealtime or bedtime when cholesterol is synthesized.
If you’ve been newly prescribed a Statin medication, find out what your baseline LDL is before starting. In other words, do you really need a Statin ASAP, or can you do a trial of nutritional & lifestyle counseling for interventions to lower LDL and improve your overall cholesterol profile. If you are already on a Statin (and especially if you are having muscle pain weakness, swelling, inflammation), ask your doctor to check your direct CoQ10 level via CardioION test (by Genova Lab). Then a more sensitive test called Hydroxymethylglutarate from an organic acid (urine) assay can later tell if a particular CoQ10 dose has been high enough for you. A starting CoQ10 dose with any Statin medication is 200 to 400mg daily.
You may also be able to switch to a milder Statin. In order of their increasing strength to lower LDL: fluvastatin (Lescol)-> lovastatin (Mevacor)-> simvistatin (Zocor)-> atrovastatin (Lipitor) -> rosuvastatin (Crestor)… AND the more cholesterol-lowering medication from different classes you are on, the more likely you will have side effects compared to taking any one of them individually (Edmunds & Mayhew, 2013).
More on cardiovascular risk management:
Visit www.FunctionalMedicineUniversity.com to find practitioners who trained in comprehensive Functional Medicine Cardiovascular Risk Lab Testing.
Sources from © 2076 Sequoia Education Systems, Inc. All Rights Reserved. Reproduction without permission prohibited.
Thomas S. R., Neuzil J., Stocker R, Inhibition of LDL oxidation by ubiquinol-10. A protective mechanism of coenzyme Q in atherogenesis? Mol Asp Med, 18 (suppl.): s 85-103, 1997.
Bargossi AM, Battino M, Gaddi A, et at. Exogenous CoQ10 preserves plasma ubiquinol levels in patients treated with 3- hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, Internal J Clin Lab Res, 24: 171-6, 1994
Fuke C, Krikorian, SA, Couris RR, Coenzyme CoQ10: A review of essential functions and clinical trials, Pharmacist, 28-41, Oct 2000
Langsjoen PH, Langsjoen AM, Coenzyme Q10 in cardiovascular disease with emphasis on heart failure and myocardial ischaemia, Asia Pacific Heart J ,7; 3: 160-168, 1998.
Langsjoen PH, et al, Treatment of statin adverse effects with supplemental coenzyme Q10 and statin drug discontinuation, BioFactors, 25 (1-4): 147-52, 2005
Langsjoen PH, et al, The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications, BioFactors, 18 (1-4): 101-11, 2003.
Mabuchi H, et al, Reduction of serum ubiquinol-10 and a ubiquinone-10 levels by atorvastatin in hypercholesterolemia, patients, J Atheroscler Thromb, 12; 2:111-19, 2005.
Lamperti C, Muscle, coenzyme Q10 level in statin-related myopathy, Arch Neurol, 62; 11: 1109-12, Nov 2005.
Mortensen AS, et al, Coenzyme Q10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure, Int J Tissue React, 12; 3: 155-62, 1990.
Folkers K, Langsjoen P, Tamagawa H, Lovastatin decreases coenzyme levels in humans, Proc Nall Acad Sci USA, 1990; 87:8931-34
Bliznakov EG, Wilkins DJ, Biochemical and clinical consequences of inhibiting coenzyme Q10 biosynthesis by lipidlowering HMG COA reductase inhibitors (statins): a critical overview, Advances in Therapy, 15; 4:219-28, Jul/Aug 1998.
Ghirlanda G, Oradei A, Manto A, et al, Evidence of plasma CoQ 10-lowering effect of HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study, J Clin Pharmacol, 33: 226-29, 1993.
Willis RA. Folkers K, Tucker JL, Tamagawa H., et al., Lovastatin decreases coenzyme Q levels in rats, Proc Nat Acad Sci USA, 87: 8928-30. 1990
Folkers K, Langsjoen P, et al, Lovastatin decreases coenzyme Q10 levels in humans, Proc Nat Acad Sci USA, 87:8931-4, 1990.
Bliznakov EG, Lipid-lowering to drugs (statins), cholesterol, and coenzyme Q10. The Baycol case-¬-a modern Pandora's box, Biomed Pharmacother, 56:56-9, 2002.
Jameson S, Statistical data support prediction of death within six months on low levels of coenzyme Ql0 and other entities, Clin Invest, 71 (suppl):137-39, 1993